Latest News About Colorectal Cancer

Here are the latest developments in colorectal cancer as of 2026, drawn from reputable sources.

• Targeted KRAS-G12C therapy shows promise in colorectal cancer. A combination of adagrasib (Krazati) with cetuximab has demonstrated tumor responses in advanced KRAS-G12C–mutant colorectal cancer and is being explored in broader settings, including localized rectal cancer in early trials. This marks progress in a historically difficult-to-treat subset and reflects a shift toward precision medicine.[1]

• Immunotherapy and combination strategies continue to expand. Recent trials and expert reviews highlight evolving immunotherapy approaches, often in combination with other agents, for subsets of colorectal cancer such as mismatch repair–deficient tumors and select mutation profiles. These strategies aim to improve outcomes and potentially reduce reliance on traditional chemotherapy in some lines of therapy.[4][5]

• Surgical and radiation approaches are being refined to reduce burden. Innovations include approaches that minimize or omit traditional radiation or surgery in select patients, leveraging targeted therapies or organ-preserving strategies, with the goal of maintaining quality of life while controlling disease.[1]

• Patient advocacy and awareness continue to shape research funding. Organizations are sustaining investments in colorectal cancer research and patient support, fueling ongoing trials and access to new therapies as they become available.[3]

• News from major cancer centers remains a key signal. Institutions like Memorial Sloan Kettering and other research centers regularly publish updates on novel therapies, early-phase trials, and vaccine initiatives aimed at prevention and relapse prevention in colorectal cancer.[9][1]

Illustration: Example treatment landscape for colorectal cancer in 2026

• Advanced KRAS-G12C–mutant tumors: KRAS-targeted therapy plus EGFR inhibitor in selected patients
• MSI-H/dMMR tumors: immunotherapy-containing regimens
• Locally advanced disease: trial-eligible strategies to reduce surgery/radiation intensity
• Risk reduction and prevention: genetic risk assessment and screening; vaccination and relapse-prevention trials

If you’d like, I can pull the most recent headlines from specific sources (e.g., major cancer centers, patient advocacy groups, or medical journals) for a dated, cited briefing tailored to your interests. I can also summarize any particular study or trial you’re curious about. Would you like a region-specific roundup (e.g., U.S. vs. global) or a focus on therapy advances, screening, or survivorship?

Citations:

• Memorial Sloan Kettering updates on new colorectal cancer treatments and KRAS-G12C targeted therapy in combination with cetuximab.[1]
• Immunotherapy and combination strategies in colorectal cancer across multiple sources.[5][4]
• Colorectal cancer news and advocacy funding updates.[3]